Jamie Smith
Medierelationer
E-mail: jamie.smith@molnlycke.com
Telefon: +46 723 757507
Mölnlycke to separate its surgical solutions business into a standalone company
Gothenburg, Sweden. 16 September 2026. Mölnlycke®, a global leader in MedTech, announces its intention to separate its Operating Room Solutions (ORS) and Gloves businesses into a new standalone company (referred to here as “Mölnlycke Surgical”). The separation is intended to create conditions for both Mölnlycke and Mölnlycke Surgical to reach their full potential and drive value creation long-term.
Mölnlycke continuously evaluates its portfolio and operating model to ensure the business is well positioned to serve both healthcare professionals and patients in the best possible way. Having delivered sustained growth across its current business areas – Wound Care, ORS, Gloves and Antiseptics – the Board has concluded that changing market dynamics, customer needs and value drivers are best addressed by operating as two standalone companies, each with sharper strategic focus, clearer accountability and greater speed of execution:
- Mölnlycke – comprising the Wound Care and Antiseptics businesses, will focus on accelerating innovation and investments addressing strategic priorities and changing customer needs. The business benefits from market-leading solutions, an established global customer base and resilient end markets. In 2025, Wound Care and Antiseptics generated net sales of c. €1.3 billion and an EBITDA margin of c. 38%.
- Mölnlycke Surgical – comprising the ORS and Gloves businesses, will focus on improving efficiency, safety and outcomes in surgical settings. The business has well established positions in key segments, a strong manufacturing footprint and benefits from continued investments in product and service innovation. In 2025, ORS and Gloves generated net sales of c. €0.8 billion and an EBITDA margin of c. 11%.
“Our ongoing assessment of Mölnlycke’s portfolio has highlighted the opportunity for two strong standalone companies, each with the focus, accountability and resources to realise its full potential and be better positioned to create long-term value,” says Karl-Henrik Sundström, Chair of the Board of Directors at Mölnlycke.
Guillaume Joucla, Interim CEO, Mölnlycke adds “We are making this move from a position of strength. Greater focus will allow both companies to move faster, invest with greater clarity and respond more effectively to evolving customer needs.”
Following the creation of Mölnlycke Surgical, the intention is that Mölnlycke and Mölnlycke Surgical will become two standalone portfolio companies under Patricia Industries’ ownership. The separation is expected to be completed during 2027, subject to customary approvals.
Each company’s capitalisation will be assessed during the process with the ambition that both companies will have a capitalisation level suited for their respective business needs, and that Mölnlycke will maintain its investment grade rating.
Mölnlycke will provide further information, including expectations on potential organisational impact, as the process proceeds.
For more information, please contact:
Seneste nyheder
-
Vi støtter Hjertegalla den 6. september. ❤️
-
Mölnlycke Health Care styrker sit globale produktionsnetværk for at understøtte fremtidig vækst inden for sårbehandling
Gøteborg, Sverige, 8. juni 2026. Mölnlycke Health Care ("Mölnlycke®"), en global leder inden for MedTech, bekræfter investeringer på samlet cirka 40 millioner euro i Mikkeli i Finland og Oldham i Storbritannien. Investeringerne styrker virksomhedens globale produktionsnetværk inden for sårbehandling ved at øge kapaciteten, optimere proceskvaliteten samt styrke robustheden og bæredygtigheden i forsyningskæden.
-
Ændrede telefontider i sommerperioden
I sommerperioden vil vores kundeservice have ændrede telefontider og i perioder reduceret bemanding. Vi gør vores bedste for at sikre en høj service og hurtig respons gennem hele sommeren.
-
Vi sponsorerer Team Rynkeby
Igen i år er Mölnlycke stolt sponsor af Team Rynkeby i deres vigtige indsats for børn med kritiske og livstruende sygdomme.
-
Mölnlycke Health Care årsrapport 2025 fremhæver bæredygtig vækst og strategisk transformation
Göteborg, Sverige. 1. april 2026. I dag har Mölnlycke Health Care offentliggjort sin årsrapport for 2025, herunder bæredygtighedsrapporten, som skitserer virksomhedens fortsatte fokus på at revolutionere plejen for både mennesker og planeten.
-
Mölnlycke tildeles EcoVadis Platinum-medalje for bæredygtighed for andet år i træk
Gøteborg, Sverige. 21. august 2025. Mölnlycke®, en verdensførende MedTech-virksomhed, er endnu en gang blevet anerkendt som en global leder inden for bæredygtighed og har for andet år i træk modtaget den prestigefyldte EcoVadis Platinum-medalje.
-
Cirkulært design er vigtigt for en klimasmart sundhedssektor
Mölnlycke stræber efter at være på forkant med at drive dekarbonisering af sundhedssektoren. I december 2024 var vi med i Dagens Medicins kampagne med fokus på bæredygtig sundhedspleje. Caterina Camerani, VP Sustainability hos Mölnlycke, forklarede, hvordan Mölnlycke kan bidrage til at reducere klimapåvirkningen fra sundhedssektoren generelt og operationsstuer i særdeleshed.
-
Juli – højsæson for grill og grillrelaterede forbrændinger
Juli betyder grillsæson for mange – men lad os ikke glemme vigtigheden af sikkerhed. Denne måned har det højeste antal grillrelaterede brande og rapporterede forbrændinger. Hos Mölnlycke er din sikkerhed vores prioritet, og derfor har vi spurgt eksperter om deres bedste råd til førstehjælp og forebyggelse af forbrændinger i sommervarmen. Hav en sikker sommer!"
-
Mölnlyckes Science Based Targets er valideret
Science Based Targets-initiativet (SBTi) har valideret, at de mål for reduktion af drivhusgasemissioner, der er indsendt af Mölnlycke Health Care, er i overensstemmelse med SBTi-kriterierne og -anbefalingerne og er i overensstemmelse med 1,5 °C forløbet. Dette er det næste skridt mod Mölnlyckes ambition om at hjælpe med at dekarbonisere sundhedsplejen.